Istari Oncology
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Istari Oncology sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Istari Oncology: 8 sponsored US clinical trials, none currently recruiting.
Istari Oncology sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Supratentorial Glioblastoma, with 1 trials.
Upper-quartile sponsor footprint
Istari Oncology sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
8 total, page 1 of 1
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
NCT04690699
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
NCT04577807
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
NCT04479241
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
NCT03564782
PVSRIPO for Patients With Unresectable Melanoma
NCT03712358
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
NCT03043391
Lerapolturev in Recurrent Malignant Glioma
NCT02986178
PVSRIPO for Recurrent Glioblastoma (GBM)
NCT01491893
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
Therapeutic Areas
How the Istari Oncology early-phase archive is shaped
8 indexed studies, none listed as recruiting (0% open); 6 completed (75%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Supratentorial Glioblastoma (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Istari Oncology: archived-pipeline peers nationwide
Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Istari Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 archived trials
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Istari Oncology page
8 registered trials is a research-attention snapshot, not an endorsement of Istari Oncology or any single study.
- None of Istari Oncology's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Supratentorial Glioblastoma is the condition Istari Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Supratentorial Glioblastoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Istari Oncology pipeline card: 8 registered trials from official public datasets.Report a data error.